ixabepilone (BMS-247550)
Jump to navigation
Jump to search
Indications
Contraindications
- hepatic dysfunction (serum ALT or serum AST > 2.5x upper limit of normal, or serum bilirubin elevated)
Dosage
Monitor
- serum ALT, serum AST, & serum bilirubin at baseline & as needed during treatment (see contraindications)[5]
Adverse effects
- fatigue (13%)
- myalgia (8%)
- mucositis (6%)
- sensory neuropathy (28%)
- motor neuropathy (1/23 patients)
Mechanism of action
- microtubule stabilization
- interaction with microtubules differs from taxanes
- induces apoptosis
More general terms
References
- ↑ Perez EA et al, Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007, 25:3407 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17606974
- ↑ Thomas E et al, Phase II clinical trial of ixbepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007, 25:3399 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17606975
- ↑ Dendeluri N et al Phase II trial of ixabepilone, en epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes J Clin Oncol 2007, 25:3421 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17606971
- ↑ Roche H et al, Phase II clinical trial of ixbepilone (BMS-247550), an epothilone B analog, as first line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007, 25:3415 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17606972
- ↑ 5.0 5.1 Prescriber's Letter 17(7): 2010 Recommended Lab Monitoring for Common Medications Liver Function Test Scheduling Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260704&pb=PRL (subscription needed) http://www.prescribersletter.com